NASDAQ:JAGX Jaguar Health - JAGX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.19 -0.30 (-6.68%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.16▼$4.5250-Day Range$0.08▼$5.4352-Week Range$4.16▼$61.49Volume303,075 shsAverage Volume410,867 shsMarket Capitalization$8.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Jaguar Health (NASDAQ:JAGX) StockJaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.Read More Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address JAGX Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comJaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug DevelopmentFebruary 1, 2023 | finance.yahoo.comJaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short SellingFebruary 9, 2023 | Paradigm Press (Ad)Biden Likely HATES This VideoBiden just signed an order that wages WAR on every American Patriot. It’s an order that could make it 100% legal for the government to track your every move… That’s why Biden would HATE this video. Inside, it explains – in detail – how to beat back the government…February 1, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX)January 30, 2023 | finance.yahoo.comJaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory ExpertiseJanuary 26, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & EuropeJanuary 26, 2023 | finance.yahoo.comJaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & EuropeJanuary 25, 2023 | finance.yahoo.comJaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer ManufacturerFebruary 9, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,476%Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%...Boeing soared 4,238%...L3Harris shot up 1,628%...January 23, 2023 | investorplace.comIs Jaguar Health (JAGX) Stock Really Up 6,800%?January 23, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena BiosciencesJanuary 20, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31stJanuary 20, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports Voting Results from January 2023 Special Meeting of StockholdersJanuary 20, 2023 | finance.yahoo.comJaguar Health to Present at Lytham Partners Investor Select Conference on January 31stJanuary 20, 2023 | finance.yahoo.comJaguar Health Reports Voting Results from January 2023 Special Meeting of StockholdersJanuary 14, 2023 | benzinga.comREMINDER: Jaguar Health to Hold Investor Webcast...January 11, 2023 | finance.yahoo.comREMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive PlantsJanuary 10, 2023 | msn.com6 Psychedelics Companies Take Action: Here Are The Latest, Major AnnouncementsJanuary 10, 2023 | markets.businessinsider.comJaguar Health's JV To Develop Botanical Pharmaceutical Drug Candidates For Mental Health IllnessesJanuary 10, 2023 | finance.yahoo.comJaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health IllnessesJanuary 10, 2023 | finance.yahoo.comJaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive PlantsDecember 19, 2022 | finance.yahoo.comJaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party InvestigatorDecember 5, 2022 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related DiarrheaDecember 5, 2022 | finance.yahoo.comJaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related DiarrheaNovember 21, 2022 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related DiarrheaNovember 21, 2022 | finance.yahoo.comJaguar Health Hosts Symposium on the Management of Cancer Therapy-related DiarrheaNovember 14, 2022 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2022 Third Quarter FinancialsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address JAGX Company Calendar Last Earnings11/14/2022Today2/08/2023Next Earnings (Estimated)3/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($71.4286) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,600,000.00 Net Margins-502.84% Pretax Margin-505.58% Return on Equity-823.56% Return on Assets-104.53% Debt Debt-to-Equity Ratio5.56 Current Ratio0.94 Quick Ratio0.69 Sales & Book Value Annual Sales$4.34 million Price / Sales1.86 Cash FlowN/A Price / Cash FlowN/A Book Value$17.66 per share Price / Book0.24Miscellaneous Outstanding Shares1,930,000Free Float1,913,000Market Cap$8.09 million OptionableNot Optionable Beta1.65 Key ExecutivesLisa A. ContePresident, Chief Executive Officer & DirectorCarol R. LizakChief Financial OfficerPravin Ramsewak ChaturvediChief Scientific OfficerJonathan S. WolinChief of Staff & Chief Compliance OfficerKaren J. BrunkeExecutive VP-Corporate & Business DevelopmentKey CompetitorsGuardion Health SciencesNASDAQ:GHSINeptune Wellness SolutionsNASDAQ:NEPTBright Minds BiosciencesNASDAQ:DRUGCatalyst BiosciencesNASDAQ:CBIOArtelo BiosciencesNASDAQ:ARTLView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 4,500 shares on 2/2/2023Ownership: 0.000%Vanguard Group Inc.Sold 633,513 shares on 11/15/2022Ownership: 1.315%Citadel Advisors LLCBought 6,300 shares on 11/15/2022Ownership: 0.000%Renaissance Technologies LLCSold 456,697 shares on 11/14/2022Ownership: 0.608%View All Institutional Transactions JAGX Stock - Frequently Asked Questions How have JAGX shares performed in 2023? Jaguar Health's stock was trading at $0.0869 at the start of the year. Since then, JAGX shares have increased by 4,779.2% and is now trading at $4.24. View the best growth stocks for 2023 here. When is Jaguar Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023. View our JAGX earnings forecast. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) announced its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.12) EPS for the quarter. The biotechnology company had revenue of $3.15 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 823.56% and a negative net margin of 502.84%. When did Jaguar Health's stock split? Jaguar Health shares reverse split on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). When did Jaguar Health IPO? (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. What is Jaguar Health's stock symbol? Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX." Who are Jaguar Health's major shareholders? Jaguar Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jaguar Health's stock price today? One share of JAGX stock can currently be purchased for approximately $4.24. How much money does Jaguar Health make? Jaguar Health (NASDAQ:JAGX) has a market capitalization of $8.18 million and generates $4.34 million in revenue each year. The biotechnology company earns $-52,600,000.00 in net income (profit) each year or ($71.4286) on an earnings per share basis. How can I contact Jaguar Health? Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The official website for the company is www.jaguaranimalhealth.com. The biotechnology company can be reached via phone at (415) 371-8300. This page (NASDAQ:JAGX) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.